- Home
- TYRA vs ZIMV Comparison
TYRA vs ZIMV Comparison
Compare TYRA & ZIMV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- ZIMV
- Stock Information
- Founded
- TYRA 2018
- ZIMV 2021
- Country
- TYRA United States
- ZIMV United States
- Employees
- TYRA N/A
- ZIMV N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- TYRA Health Care
- ZIMV Health Care
- Exchange
- TYRA Nasdaq
- ZIMV Nasdaq
- Market Cap
- TYRA 571.9M
- ZIMV 530.7M
- IPO Year
- TYRA 2021
- ZIMV N/A
- Fundamental
- Price
- TYRA $11.71
- ZIMV $18.95
- Analyst Decision
- TYRA Strong Buy
- ZIMV Hold
- Analyst Count
- TYRA 7
- ZIMV 3
- Target Price
- TYRA $30.43
- ZIMV $14.50
- AVG Volume (30 Days)
- TYRA 201.1K
- ZIMV 514.7K
- Earning Date
- TYRA 08-14-2025
- ZIMV 07-30-2025
- Dividend Yield
- TYRA N/A
- ZIMV N/A
- EPS Growth
- TYRA N/A
- ZIMV N/A
- EPS
- TYRA N/A
- ZIMV N/A
- Revenue
- TYRA N/A
- ZIMV $443,402,000.00
- Revenue This Year
- TYRA N/A
- ZIMV $2.09
- Revenue Next Year
- TYRA N/A
- ZIMV $1.64
- P/E Ratio
- TYRA N/A
- ZIMV N/A
- Revenue Growth
- TYRA N/A
- ZIMV N/A
- 52 Week Low
- TYRA $6.42
- ZIMV $8.15
- 52 Week High
- TYRA $29.60
- ZIMV $19.00
- Technical
- Relative Strength Index (RSI)
- TYRA 61.31
- ZIMV 84.08
- Support Level
- TYRA $9.96
- ZIMV $18.92
- Resistance Level
- TYRA $11.48
- ZIMV $18.95
- Average True Range (ATR)
- TYRA 0.73
- ZIMV 0.08
- MACD
- TYRA 0.06
- ZIMV -0.33
- Stochastic Oscillator
- TYRA 75.43
- ZIMV 77.55
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.